|
Intra cellular Therapies Inc (NASDAQ: ITCI) |
|
Intra cellular Therapies Inc
ITCI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Intra Cellular Therapies Inc growth rates, revenue grew
by 39 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 171
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Intra Cellular Therapies Inc net loss increased from $-24 millions, to $-26 millions in III. Quarter 2024,
• More on ITCI's Growth
|
|
Intra Cellular Therapies Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 36.58 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
1889.56 |
PE TTM
|
|
Company's Price to Sales ratio is at 21.75.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.88.
• More on ITCI's Valuation
|
|
|
|
|
Intra Cellular Therapies Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 36.58 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
1889.56 |
PE TTM
|
|
Company's Price to Sales ratio is at 21.75.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.88.
Intra Cellular Therapies Inc Price to Book Ratio is at 11.66 lower than Industry Avg. of 829.09. and higher than S&P 500 Avg. of 0.01
• More on ITCI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com